Sequential Skin Ltd.’s first-in-class Microbiome Testing Platform to empower Consumers and Companies
Tokyo, May 25th 2023 — Corundum Systems Biology Inc., a Japan-based company that brings together microbiome research and business creation, has newly invested in Sequential Skin Ltd., a microbiome start-up focused on creating a world with healthier microbiomes. The investment is Corundum Systems Biology’s first direct investment in the field of skin microbiome.
Sequential is the industry leader in microbiome testing, claims substantiation and support for brands formulating products for skin, scalp, intimate care and oral care. Recognized as one of the industry’s most significant testing solution providers, Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. Sequential’s testing is exclusively managed in-house and with human clinical subjects, in vivo. As an ally in research and development to top global brands and household names, Sequential supports their journey to delivering consumer-driven products backed by science.
The company has also introduced a comprehensive consumer testing kit that assesses individual skin health using quantitative real-time PCR (qPCR) and next-generation sequencing technology. The kit gives users personalized recommendations on products and active ingredients best suited for individual skin care. The product is already available for purchase.
The company, founded in 2019 by Dr. Oliver Worsley, CEO, and Dr Albert Dashi, Chief Science Officer, is supported by Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, and JLABS, a Johnson & Johnson Innovation company.
For companies: www.sequential.bio
For consumers: www.sequentialskin.com
Hidehiko Otake, CEO of Corundum Systems Biology Inc., says, “Our investment in Sequential marks our first direct investment in skin health microbiome. Sequential combines business acumen with the best of science in microbiome research and genetics to revolutionize skin health. Traditional treatment in solving skin conditions had been typically generic. We are very excited to see our investment drive momentum to this company’s breadth and reach as needs for personalized skin care continue to rise.” Corundum Systems Biology’s mission is to be an Innovation Hub in the field of microbiome, a critical field with potential to unlock next-generation life science technologies and bettering human health and quality of life: https://www.csb.co.jp/.
